Drugs / MVA-FCU1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00978107 | Sep 2009 → Sep 2011 | hepatocellular carcinoma | Transgene | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-FCU1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00978107 ↗ |
| Known as | TG4023 | “BACKGROUND: TG4023 is a modified vaccinia virus Ankara (MVA) containing the yeast-originated transgene FCU1, expressing cytosine deaminase and uracil phosphoribosyltransferase enzymes” PMID 28177438 ↗ Jan 2017 |
| Route | Other | “Percutaneous IT injection” NCT00978107 ↗ |